SPARC and Sun Pharma enter into a license agreement for SCD-044

▴ sparc-sun-pharma-collaborates-manufacturing-scd044
Sun pharma and SPARC collaborates for Sphingosine-1-P (S1P1) receptor agonist for the treatment of auto immune diseases

Sun Pharma Advanced Research Company Ltd and Sun Pharmaceutical Industries Ltd today announced a worldwide licensing agreement on thedevelopment and commercialization of SCD-044 which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.

Under terms of the license agreement, Sun Pharma will pay SPARC an upfront payment of US$ 20 million SPARC will also be eligible to receive up to US$ 125 million as milestone payments contingent upon the achievement of clinical, regulatory and sales milestones, as well as tiered royalties on sales. Sun Pharma will be responsible for the development, regulatory filings, manufacturing and commercialization of the product globally.

“SPARC is committed to progressing its pipeline to address the needs of patients. We are proud to be partnering with a global organization with a footprint in auto-immune disorders” said Anil Raghavan, CEO, SPARC. This agreement with Sun Pharma follows the recent announcement that SPARC has acquired Bioprojet SCR’s share of rights to SCD-044.

“The in-licensing of SCD-044 adds to our specialty pipeline of innovative dermatology products. It also demonstrates our commitment to this important segment with significant unmet medical needs. SCD-044 may offer an alternate treatment option for patients in this segment who require systemic treatment and may offer benefits in terms of efficacy and safety over existing oral treatments for this population. SCD-044 has the potential to improve the current oral standard of care.” said Dilip Shanghvi, Managing Director, SunPharma.

SCD-044 is a novel orally bio-available Sphingosine-1-P (S1P1) receptor agonist for the treatment of inflammatory diseases such as atopic dermatitis and psoriasis. S1P1 receptor agonists are promising for the treatment of autoimmune inflammatory diseases as they cause diminished migration of lymphocytes out of lymphatic tissue. This results in a decrease of circulating lymphocytes, thereby reducing inflammation.The phase 1 study of SCD-044 has been completed in healthy volunteers. This study established clinical proof-of-concept for SCD-044 in terms of its pharmacodynamics effects. Lymphocyte count reduction, a surrogate marker of efficacy for S1P1R agonists was observed at all dose levels evaluated.

Tags : #SunPharma #SPARC #SCD044 #Collaboration

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

From Algorithms to Actual Care: Is India’s AI Healthcare Dream Real?March 04, 2025
Lung Regeneration: Can Science Give Preterm Babies a Second Breath?March 04, 2025
Lung Regeneration: Can Science Give Preterm Babies a Second Breath?March 04, 2025
Lung Regeneration: Can Science Give Preterm Babies a Second Breath?March 04, 2025
The Great Indian Fat Crisis: Are 440 Million Overweight Indians the Price of Modernity?March 04, 2025
Neovantage Innovation Park Showcases Life Sciences Infrastructure at BioAsia 2025, Hosts Ministerial Visit and Miltenyi Biotec InaugurationMarch 03, 2025
University of Manchester invites applications for MA Digital Media, Culture and SocietyMarch 03, 2025
#EndLeprosy pathway is through stopping stigma against affected personsMarch 03, 2025
1.5 Million Bottles Recalled: Is Your ADHD Medication Safe?March 03, 2025
Dressed for Trust: Why Doctors Must Wear White Aprons AgainMarch 03, 2025
India’s Pharma Revolution: Can New Regulatory Reforms Unleash a $42 Billion Industry?March 01, 2025
Pregnant and Pained: Is Paracetamol Poisoning Our Unborn Children?March 01, 2025
Are Your Idlis Poisoning You? The Hidden Dangers of Plastic in Indian KitchensMarch 01, 2025
Rela Hospital Launches India’s First Intestinal Rehabilitation Centre to Expand Treatment Horizons Beyond TransplantationFebruary 28, 2025
Rela Hospital Launches India’s First Intestinal Rehabilitation Centre to Expand Treatment Horizons Beyond TransplantationFebruary 28, 2025
Olympus Announces Milestone for iTind(TM) Device with Expanded Availability Across Major APAC MarketsFebruary 28, 2025
7 Simple Breathing Exercises to Strengthen Your LungsFebruary 28, 2025
MedGenome launches Campaign ‘Care for the Rare’ to promote early detection of Rare DiseasesFebruary 27, 2025
Stuck in Slow Motion: How Bureaucracy is Choking India’s Pharma DreamFebruary 27, 2025
A New Spine, A New Life: Inside Kerala’s First 3D-Printed Titanium Cage SurgeryFebruary 27, 2025